A Company Built from Lived Experience, Vision, and Proof

For more than five years, Acclinate has been building what the industry could not: a scalable, trusted pathway that brings real people into research and converts that trust into predictive, representative data.

Our Story

Built from Necessity

Founded by Del Smith and Tiffany Whitlow, Acclinate exists because traditional clinical research has never been designed with, or for, the communities most impacted by disease.

Where others saw recruitment challenges, they saw:

  • A trust gap
  • A data gap
  • An opportunity to build differently

Their lived experience, combined with deep expertise in genomics, community engagement, and enterprise operations, shaped a new category at the intersection of Touch + Tech.

Today, Acclinate is a national, enterprise-level company serving 7 of the top 10 Pharma companies with patented technology, exclusive community access, and the operational rigor required to scale trust.

Our Founders

Tiffany Whitlow

Co-Founder & Chief Development Officer

Tiffany brings decades of community engagement, brand strategy, and culturally relevant communication experience. She architected the core of NOWINCLUDED, ensuring it is not a database, but a trusted space, built with integrity, belonging, and cultural care.

Tiffany ensures Acclinate scales community trust with the same authenticity it was built on.

Her leadership has driven:

100+ national community events

Millions of educational impressions

Deep, lasting partnerships across advocacy, health systems, and trusted local leaders

A tech foundation grounded in human relationships

Del Smith, PhD

Co-Founder & CEO

Del saw firsthand how lack of representation limits the quality, accuracy, and impact of scientific discovery. Drawing from his background in genomics, academia, and healthcare innovation, he built Acclinate on the belief that representative data leads to better science and smarter business.

Del is a national voice championing the idea that health equity is achieved through engagement, not extraction.

Under Del’s leadership, Acclinate has grown from a mission-driven idea to a market leader with:

A 200K+ member national community

A patented AI/ML engine (e-DICT)

Partnerships with the world’s most influential sponsors

A category-defining approach to representative enrollment intelligence

Our Founders

How we’re Different

Always-on community trust

5+ years of proven national engagement

Exclusive representative data signals

Patented predictive AI/ML

Exclusive representative data signals

Real-world behavioral insights

Enterprise-scale operations

Our Vision

Health Equity, Realized.

Our Mission

Empowering Communities to Take Actions for Better Health

Customer Success Stories

Trusted Voices, Proven Impact

MMR

Fostering Health Equity in Multiple Myeloma Research

Multiple myeloma is the most common hematologic malignancy among Black & African Americans.1 However, they comprise only 4% of enrollees in clinical trials supporting FDA approval of multiple myeloma drugs.2 Acclinate collaborated with the Multiple Myeloma Research Foundation (MMRF) from April to October 2024 to address this disparity and support more representative research.
Read Case Study
83%-95%
of attendees felt comfortable participating in discussions about their health
9.6%-62%
reported limited knowledge of clinical trials before the events
32.3%-83%
felt more informed about clinical research after these events

Where We've Been Featured

See some places we’ve been featured and read the latest company announcements.

No items found.
No items found.
No items found.